Objectives: Our goal was to evaluate stereotactic ablative radiotherapy (SABR) as a salvage option for isolated recurrence of NSCLC in the lung parenchyma after definitive treatment of stage I to III disease.
Introduction
Uncontrolled tumors are a major source of seeding to distant organs that can cause treatment failure in patients with recurrent or second primary lung cancer. Undoubtedly, definitive local treatment is required to achieve optimal outcomes when isolated recurrence and possibly new primaries emerge after definitive treatment for any stage of NSCLC. Local tumor recurrence develops in about 5% to 40% of patients with NSCLC even after they have received definitive standard treatment, and the likelihood of recurrence increases in patients with more advanced disease. [1] [2] [3] In addition, a substantial proportion of patients experience isolated lung parenchymal recurrence/metastasis, which occurs in a different lobe/lung than the primary tumor, 4 or a second primary lung cancer (estimated risk 1%-6% per person-year). 5, 6 Thus, there is a great need for effective and aggressive local treatments that can produce durable local control and a potential cure if recurrence occurs. Such treatments should have minimal toxicity because many NSCLC patients have reduced tolerance of toxic effects after having undergone aggressive treatment for their primary lung cancer.
Currently, the National Comprehensive Cancer Network guidelines for NSCLC recommend re-resection as the preferred modality for patients with resectable locoregional recurrence; the recommendation is based on data from small retrospective studies, and the indications, effectiveness, feasibility, safety, and long-term outcomes of re-resection remain unclear. [7] [8] [9] In particular, there is very limited reporting about salvage surgery for isolated recurrence or isolated distant metastasis in lung parenchyma, as many patients might have poor lung capacity and/or co-morbidities after definitive treatment. 10 Stereotactic ablative radiotherapy (SABR), with its high local control rate and minimal toxicity, has emerged as an alternative local modality for recurrent or second primary NSCLC. [11] [12] [13] However, large prospective studies with robust long-term data are needed to illustrate patient survival, toxic effects, and disease control outcomes after SABR in this unique patient cohort. This is the first report of such a study. Our prospective phase II clinical trial investigated patterns of treatment failure, patient survival, and safety in patients with isolated lung parenchymal recurrence of NSCLC treated with salvage SABR who were followed for 5 years thereafter.
Materials and Methods

Patients and Study Design
From November 2005 to March 2013, patients with an isolated lung parenchymal recurrence of NSCLC who were treated at The University of Texas M. D. Anderson Cancer Center and met all inclusion criteria were eligible to enroll in this SABR trial. This study was approved by the institutional review board of M. D. Anderson, and all patients provided written informed consent to participate.
The inclusion criteria for the study were as follows. Patients had to have a histologically documented history of prior NSCLC and isolated lung parenchymal recurrence of NSCLC, 3 cm or smaller and suitable for SABR (including meeting dose volume constraints and ability to comply with clinical setup and delivery), without evidence of lymph node involvement or extrathoracic disease after definitive treatment for prior NSCLC. Operable patients who elected to have SABR were also eligible. Histologic confirmation of recurrent NSCLC was highly recommended. When confirmed histologically, it had to have the same histologic characteristics as the initial NSCLC and could be located in the same lobe (termed local recurrence) of the lung or in a different lobe (including the opposite lung) after an otherwise tumor-free interval. Because we could not rule out the possibility of recurrence in patients with more than 4 years of follow-up after completion of treatment, or a subsequent lesion of the same histologic type arising less than 6 months after diagnosis of the first lesion, these patients were eligible for and included in the study as recurrence, although the possibility of a secondary primary or synchronous tumors are among the differential diagnosis. 11, 14 Patients who received systemic therapy in addition to SABR were also eligible. Patients who had a new tumor with different pathologic characteristics (that was for sure a second primary lung tumor) were excluded.
The restaging work-up included computed tomography (CT), 18 F-fluorodeoxyglucose positron emission tomography (PET)/CT, and brain magnetic resonance imaging within 3 months before SABR. Clinical staging of the previous NSCLC was done according to the sixth edition of the American Joint Committee on Cancer's TNM staging system. Patients with hilar or mediastinal lymph nodes larger than 1 cm on CT or abnormal PET studies underwent endobronchial ultrasonography (EBUS) to rule out regional disease.
SABR
For SABR, all patients underwent four-dimensional CT-based simulation with free-breathing, gated techniques to manage tumor motion. Repeated breath hold scans were acquired when indicated (motion >1 cm). The internal gross target volume (IGTV) was contoured according to the maximal intensity projection. 15 Imageguided stereotactic body radiotherapy with a dose of 50 Gy in four fractions was prescribed to the planning target volume (PTV). For patients with local recurrence (in the field of previous radiotherapy), compromised PTV coverage or an alternative prescription dose was allowed to meet with normal tissue dose constraints. We optimized our unmodulated, three-dimensional, conformal radiotherapy or intensity-modulated radiotherapy SABR plans using 6 to 12 coplanar or noncoplanar 6-MV photon beams. A prescribed isodose line was required to cover more than 95% of the PTV and 100% of the IGTV without margin. We defined centrally located lesions, conducted detailed stereotactic body radiotherapy simulations, and constrained the planning and dose volumes as described previously. 16, 17 
Follow-up Evaluations
Patient follow-up included chest CT 6 weeks after salvage SABR, then every 3 months for the first 2 years, then every 6 months for the next 3 years, and then annually. PET/CT was required 3 to 12 months after SABR. Local recurrence (LR) was defined as a recurrence or new lesion that occurred in the same lobe over time and corresponded to avid areas on PET/CT and/or was confirmed histologically after SABR. LR was classified as in-field recurrence (occurring in the area inside the PTV), involved lobe failure (occurring in the same lobe outside the PTV), or marginal failure (recurrent lesion located within 1 cm of the PTV in any direction).
Regional recurrences (RRs) and distant metastases (DMs) after salvage SABR were documented. RR was defined as any intrathoracic lymph node relapse outside the PTV. A recurrence appearing in a different lobe or in an extrathoracic site was considered DM. Any adverse events definitely or possibly associated with SABR were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0.
Statistical Analysis
The primary end point was progression-free survival (PFS). Secondary end points were overall survival (OS), pattern of failure, toxicity, and predictive factors associated with prognosis in exploratory analysis. PFS was calculated from the beginning date of salvage SABR to the date of any new recurrence (the date of the first image that showed abnormalities) or death (without confirmed recurrence). OS was calculated from the beginning date of salvage SABR to the date of death from any cause or last follow-up. The final data analyses were based on information received as of November 1, 2016 .
We compared categorical data with c 2 test statistics; continuous data were compared with t tests. The median follow-up duration was estimated by the reverse Kaplan-Meier method. 18 According to the Kaplan-Meier method, survival curves were compared using the log-rank test. Univariate and multivariate Cox proportional hazards models were performed to obtain prognostic factors and corresponding hazard ratios for different factors with 95% confidence intervals. Clinical variables in univariate analysis included age, sex, tumor size, EBUS, Eastern Cooperative Oncology Group (ECOG) status, histologic type, maximum standardized uptake value (SUV max ) of tumor, IGTV, PTV, diagnosis interval between the primary and recurrent tumor, pre-and post-SABR pulmonary function, and type of recurrence event. Pre-and post-SABR immunologic and inflammatory markers in peripheral blood, including neutrophil and lymphocyte counts acting as potential reflectors of immune status, were included in this exploratory analysis. Factors with p values less than 0.05 in univariate analysis were entered into multivariate analysis.
When the probability of any recurrence event was estimated, we calculated the probability of death as a competing risk event to overcome the overestimated probabilities of both events by using competing risk analysis. 19 All analyses was performed using IBM SPSS 21.0 software (IBM, Inc., Armonk, NY) with a macro to calculate the cumulative incidence competing risk. 20 All significance tests were two tailed, with significance set at p less than 0.05.
Results
Patient Characteristics
Among 65 patients screened, 59 patients were eligible and evaluable for the study (see Supplementary  Fig. 1 , which is a flowchart of patients enrolled in the trial). Table 1 summarizes patient and disease characteristics. All patients had PET/CT staging, and biopsies of 57 recurrent tumors (97%) biopsy were performed to confirm the same histologic type as prior NSCLC. Two lesions not examined by biopsy owing to severe comorbidities were considered to have recurrent disease on the basis of serial CT and PET/CT images. Six patients (10%) underwent hilar and mediastinal pathologic staging (EBUS procedure) before salvage SABR. The median interval between the diagnosis of prior NSCLC and recurrence was 30 months (range 2-132 months), and in most patients (69%) recurrence developed within 4 years.
As listed in Table 1 , 41 patients (69%) had undergone a thoracic operation, and 33 (56%) had been previously treated with thoracic radiation: five had received prior SABR (50 Gy in four fractions for four patients and 50 Gy in five fractions for one patient) and 28 had received conventional external beam a Unless otherwise specified. b Two lesions with typical imaging feature were highly suggestive of malignancy. One lesion was involved lobe failure with an SUV max value of 9.2 and another lesion was in-field recurrence with SUV max value of 5.0. They were not confirmed histologically because of the high risk associated with biopsy. Forty patients were treated with lobectomy/limited resection and one patient was treated with pneumonectomy. Four patients had twice undergone thoracic surgery, and one patient had undergone thoracic surgery three times. d Tumor was measured on CT imaging within 2 months before SABR. e Two patients who had undergone thoracic irradiation previously received 40 Gy in four fractions in the same lung to meet normal tissue dose constraints. BED, biological equivalent dose; ECOG, Eastern Cooperative Oncology Group; IGTV, internal gross target volume; NOS, not otherwise specified; NSC, non-small cell carcinoma; PTV, planning target volume; SABR, stereotactic ablative radiotherapy; SUV max , maximum standardized uptake value.
radiotherapy with a median delivered dose of 66 Gy (range 48.8-87.5 Gy). The median time from the end date of previous radiotherapy to the start of salvage SABR was 27.5 months (range 2-61 months). Onethird of patients (34%) were potentially operable before SABR and the rest were considered inoperable on the basis of lung capacity and/or comorbidities.
Two patients received chemotherapy after salvage SABR. Nine tumors (15%) treated with salvage SABR were locally recurrent disease in the same lobe, and most tumors (50 [85%]) developed in a different lobe. Only two patients had overlapping PTV volumes between SABR and prior radiotherapy.
Pattern of Treatment Failure and Patient Survival after SABR
At a median follow-up of 58.3 months (interquartile range 43.9-85.3 months), a total of 19 patients (32%) experienced recurrence at a median of 13.3 months after salvage SABR (range 4.2-28.3 months [Fig. 1A] ). Only three patients (5%) had LR as a first event (two had in-field recurrence and one had involved lobe failure); this occurred 8.5, 10.6, and 25.9 months after SABR, respectively. The SUV max values of the three recurrent lesions were 1.3, 19.4, and 17.3, respectively, and the first two lesions were confirmed pathologically. The estimated cumulative incidence rates for LR, which were calculated by using the competing risk method, were 3.5% at 1 year, 5.2% at 3 years, and 5.2% at 5 years (see Fig. 1A ).
Six patients (10%) had RR as the first event at a median interval of 10.8 months (range 4.7-28.3 months), including simultaneous RR and DM, which occurred in three patients. DM as a first event occurred in 13 patients (22%) at a median interval of 13.3 months (range 4.2-25.9 months), and the most common metastatic site was the lung (nine patients [69%]). The estimated cumulative incidence rates for RR were 5.1% at 1 year and 10.3% at 3 years; for DM, they were 10.3% at 1 year and 22.4% at 3 years. The corresponding 5-year rates were the same as the 3-year rates because no events occurred after 3 years.
Twenty-nine patients treated with salvage SABR (49%) died; 16 of them (27%) died of lung cancer. The estimated OS rate at 5 years was 56.5%, and the median OS was 63.8 months (Fig. 1B) . The OS rate reached as high as 74.1% at 5 years and 60.7% at 7 years (median OS 119.9 months) if it was calculated from diagnosis of the prior tumor instead of from the date of salvage SABR. When survival rates were compared by prior NSCLC stage, patients with initial stage I disease had significantly longer PFS and a trend of longer OS than did patients with stage II or Z disease (median PFS not reached versus 28.3 months, p ¼ 0.013; median OS ¼ 81.7 versus 41.9 months, p ¼ 0.072 [ Fig. 2A and B] ).
Of the six patients in whom only LR or RR developed after salvage SABR, four received a second local salvage treatment (including an operation, radiation, or chemoradiation), one received chemotherapy, and one did not receive salvage treatment; a subsequent recurrence Estimation of 95% confidence interval (CI) is limited. RR, regional recurrence.
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Long-Term Outcomes of Salvage SABR for NSCLCdeveloped in four patients (one had RR and three had DM). Of 13 patients who had distant failure after SABR, eight received treatment: four had target therapy, two had SABR, and two had chemotherapy. A subsequent recurrence developed in 12 patients (92%) (four had a subsequent LR and eight had a subsequent DM). Median OS time in the 13 patients with DM after salvage SABR was significantly poorer than that in patients without recurrence and patients with locoregional recurrence alone (LRR) (30.9 months versus not reached [p ¼ 0.006]; p ¼ 0.023 among the three groups [ Fig. 2C]) . However, there was no difference of OS between patients with LRR and patients without recurrence (p ¼ 0.811).
Prognostic and/or Predictive Factors of Survival
The potential predictors of PFS and OS after salvage SABR were analyzed using a Cox proportional hazards model (Table 2 ). Univariate analysis showed that several clinical factors, including ECOG performance status, histologic type, and pre-and post-SABR carbon monoxide diffusing capacity (DLCO) were all significantly associated with PFS and OS (p < 0.05). Notably, the post-SABR neutrophil-to-lymphocyte ratio (NLR), an immunologic and inflammatory marker, was significantly associated with both PFS and OS, and a high post-SABR NLR value predicted poor prognosis (p < 0.05). The median post-SABR NLR value was 3.44 (range 1.39-14.19) and the mean value was 4.00. The median pre-and post-SABR absolute lymphocyte count values were 1.49 (range 0.48-4.29) and 1.16 (range 0.36-3.51), and the corresponding mean values were 1.57 and 1.34, respectively. We also analyzed the survival impact of the time from the prior lung cancer until the diagnosis for the recurrence; the result showed no significant difference, with a p value of 0.7.
In the multivariate analysis, tumor size and post-SABR NLR were not significant predictors for PFS (p ¼ 0.052 and 0.065, respectively). However, post-SABR NLR was predictive of OS (hazard ratio ¼ 1.33; 95% confidence interval: 1.06-1.65; p ¼ 0.012); each one-unit increase in NLR increased the risk of death by about 33%. ECOG status and pre-SABR DLCO, which indicate a patient's health status, were not significantly associated with OS (p ¼ 0.122 and 0.092, respectively). Owing to the small sample size, all of the aforementioned analyses should be considered exploratory and validation is needed.
Adverse Events
A comparison between pre-and post-SABR pulmonary function tests showed a significant difference in DLCO, which may be associated with SABR (p < 0.001). However, there was no difference between pre-and post-SABR values for forced expiratory volume in the first second of expiration (Table 3) . At baseline assessment, 24 patients (41%) had dyspnea or shortness of breath because of comorbidities and/or prior treatment; five patients (8%) had dyspnea classified as grade 3 owing to the need for oxygen (see Supplementary Table 1 , which shows this symptom before and after SABR). Other less frequent symptoms at baseline included cough, fatigue, and weakness. If dyspnea is present before SABR, accurate toxicity grading after SABR is difficult to determine because the Common Toxicity Criteria definition of pulmonary toxicity does not distinguish between baseline dyspnea and changes in the condition and dyspnea after SABR could reflect normal progression of pulmonary disease.
The most common acute adverse events after SABR were radiation pneumonitis and chest wall pain (Table 4) . When five patients with grade 2 dyspnea at baseline were excluded, a total of 18 patients (31%) had grade 2 adverse events after SABR; 14 of them had undergone prior thoracic radiation, and nine had had a prior operation. In all, only three patients (5%) experienced grade 3 SABR-related adverse events: one (2%), who had received prior thoracic radiation with a dose of 66 Gy in 33 fractions, had dermatitis and two (3%) had radiation pneumonitis. One of the two patients with radiation pneumonitis had had an operation twice and had SABR delivered to the same lobe that had been treated with a prior wedge resection, and the other patient had previously received radiotherapy with 63 Gy in 35 fractions; both patients had 
Discussion
This prospective clinical study showed excellent local control of 94.8% at 5 years when SABR was used as salvage treatment for isolated recurrence of NSCLC in the lung parenchyma. Further, the post-salvage cumulative incidence of RR was only 10.3% at 5 years, mirroring the reported data for RR rates after primary early-stage NSCLC treated with definitive SABR or surgery. 2, 21, 22 However, despite the excellent locoregional control with salvage SABR, the cumulative DM rate (22.4% at 3 years) appears higher than what is expected for patients treated definitively for primary early-stage disease. 2, [21] [22] [23] In addition, the median intervals to recurrence were relatively short after salvage SABR (about 1 year) as compared with that for primary early stage NSCLC treated with SABR (typically about 1.5 years). The fact that all recurrence events occurred within 2.5 years after salvage SABR also differs from the outcomes for patients with primary early-stage disease treated with definitive surgery or SABR, in whom late recurrence events after 4 years have been reported. 2, 24 Therefore, although salvage is extremely effective for locoregional control, these patients with recurrence are still at relatively high risk for distant failure.
Ultimately, it is difficult to judge whether the DM events we observed were attributable to failed salvage SABR or to preexisting distant seeding from the prior tumor. Indeed, patients in whom subsequent DM developed after salvage SABR had a worse OS than patients in whom DM did not develop. Consequently, the high DM rate, the short interval to recurrence, and the associated morbidity of such events after salvage SABR reflect the intrinsic nature of recurrent disease. Together, they suggest that recurrence or presence of a new lung lesion heralds a more aggressive disease course and biology. Identifying that most recurrences occurred within 2.5 years after salvage SABR however helps clinical physicians recognize that vigilant screening and follow-up during this time is prudent and helps patients become better informed about the risks and expectations for disease recurrence. Further, given the relatively high DM rate (one in four patients will experience DM within 2.5 years), these results suggest that many patients may benefit from systemic treatment in addition to local therapy at the time of local recurrence. However, identifying which subsets of patients would benefit from the addition of systemic therapy, and which systemic therapy, remains to be revealed.
It is highly noteworthy that, in spite of the high DM rate, in the present study, the 5-year OS rate after salvage SABR was as high as 56.5%, which is similar to the OS rate for patients with primary stage _ NSCLC treated with definitive SABR. [25] [26] [27] With calculation from the date of initial primary NSCLC diagnosis, the OS rate was even higher, at an impressive 74.1% at 5 years. This suggests that overall, most patients with isolated local lung parenchymal disease are likely to do as well as patients with primary early stage lung cancer on the whole and their disease is still highly curable. These findings echo recent studies reporting that better cancerspecific outcomes are achieved when bulky disease burden is aggressively locally controlled, such as in the oligometastatic setting, and closely represent the 5-year OS rates after diagnosis of a second lung primary after definitive treatment. 4, 5, 11 Given the high OS rates shown in our study, eradicating local tumors is an essential step in obtaining a cure or better prognosis.
In attempting to understand which patients will fare better with salvage SABR, we found that several important clinical factors were associated with survival outcomes. Notably, an exploratory analysis of the post-SABR NLR, which partially reflects the balance between the host's protumor inflammatory status and antitumor immune status, found that it correlates with OS. It has been documented that the antitumor effects of immunotherapy and radiation are carried out by lymphocytes (specifically, CD8-positive effector cells), 28 and some researchers have argued that the lasting effects of SABR may in fact be partly mediated by immune mechanisms. 29, 30 Therefore, it is not surprising that a high NLR, which indicates that a patient has a lower number of lymphocytes (the cells responsible for antitumor effects relative to neutrophils), may be a marker of poor response and survival after SABR. This exploratory result needs further validation and may potentially help to guide our future research directions.
Finally, with respect to SABR toxicity, our study showed that salvage SABR was well tolerated and that it had a very low toxicity profile; only 5% of patients experienced grade 3 adverse events. Even counting the three patients whose need for oxygen increased after-SABR compared with their need at baseline, only 5 patients (8%) had grade 3 radiation pneumonitis. It will be important for future studies to recognize symptom changes in patients who had severe symptoms at baseline and to apply specific criteria for toxicity grading. A reasonable explanation of the low toxicity we observed is that most tumors in our patients were peripheral small tumors, and almost half of our patients had not previously received radiotherapy; in contrast, most other published studies included patients who had previously received radiotherapy. 31 In the 54% of patients in our study who had previously received radiotherapy, SABR was delivered to lesions with minimal overlap of the prior target volume, so that normal tissue would receive a relatively acceptable cumulative dose of radiation. There are several limitations in the present study. First, because of challenges in confirming the origin of the cancer, we cannot rule out the possibility that some of our recurrent cases may represent secondary lung cancer even though the histologic type is the same. 14 Second, this is a highly selective patient population, with isolated lung parenchymal lesions 3 cm or smaller; it represents a very early stage of recurrence or isolated metastasis. Third, determining who may fail shortly after salvage SABR and need systemic therapy after SABR remains investigational.
In conclusion, this study represents one of the largest studies-and the first prospective study-of salvage SABR for isolated lung parenchymal recurrence of NSCLC. Our results demonstrated excellent local control, low toxicity, and very promising survival rates, with a long-term follow-up of nearly 5 years. Importantly, in most patients recurrence did not develop after SABR. These results indicate that the survival of patients with either isolated NSCLC recurrence or possibly a second primary NSCLC could be enhanced through both close surveillance after initial treatment to detect lesions at an early stage and treatment of new lesions with SABR to obtain optimal local control. On the basis of our findings, we consider SABR to be a very effective and safe salvage strategy that should be strongly recommended for patients with isolated small (3 cm) lung parenchymal recurrent NSCLC and may be considered as a first-line treatment along with surgery for isolated lung parenchymal recurrence.
